Equity Profile

BMY

Bristol-Myers Squibb Company

Health CarePharmaceuticals$121.2B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. As part of the Health Care sector, it plays a crucial role in addressing unmet medical needs, particularly in oncology, immunology, and cardiovascular diseases.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and revenues.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market presence and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BMY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+12.21%

Avg Stock Reaction

+2.95%

Last Quarter Recap

In Q1-2026, Bristol-Myers Squibb reported an EPS of $1.58, exceeding expectations by 9.65%. The stock reacted positively, gaining 5.21% the following day.

Management Promises & Guidance

Continue to advance key pipeline candidates.
Focus on improving operational efficiency.
Commit to enhancing shareholder value.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's strong history of beating EPS estimates. However, concerns about revenue growth and pipeline developments linger.

Bull Case

If Bristol-Myers Squibb can deliver strong EPS and positive updates on its drug pipeline, it could lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides disappointing updates on its pipeline, it could result in a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's strong history of EPS surprises, this number will be critical in determining market sentiment.

What updates will be provided on the drug pipeline?

Investors will closely watch for any advancements or setbacks in the pipeline, as these can significantly affect future revenue.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Bristol-Myers Squibb's pipeline to deliver unexpected results, particularly in oncology.

Supporting Evidence

The company has a strong track record of exceeding EPS estimates, with an 88% beat rate over the last eight quarters.

Options pricing suggests a relatively low expected move compared to historical averages, indicating potential for a larger surprise.

Key Risk

If pipeline updates reveal significant advancements, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bristol-Myers Squibb can maintain its strong earnings trajectory amidst competitive pressures and pipeline challenges.

Bull Confirmed If

An EPS of $1.70 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.40 would raise concerns about profitability and future growth.

Pre-Earnings Positioning

Options Market

Implied Move

±4.83%

Historical Avg

±5.4%

In line with history

The options market is pricing in a move of about 4.83%, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±4.8% while BMY has averaged ±5.4% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.3%

30d HV

25.7%

Calls (1.0M)P/C Ratio: 1.07Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bristol-Myers Squibb beats EPS expectations, history suggests a potential stock increase of around 4.21%, confirming the bullish outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline of about 5.81%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the performance of key drugs in the pipeline.
2Updates on regulatory approvals or clinical trial results.
3Management's outlook on revenue growth for the upcoming quarters.
4Insights into cost management strategies and operational efficiency.
5Any changes in guidance or strategic priorities.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and revenues.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market presence and product offerings.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BMY Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+12.21%

Avg Stock Reaction

+2.95%

Last Quarter Recap

In Q1-2026, Bristol-Myers Squibb reported an EPS of $1.58, exceeding expectations by 9.65%. The stock reacted positively, gaining 5.21% the following day.

Management Promises & Guidance

Continue to advance key pipeline candidates.
Focus on improving operational efficiency.
Commit to enhancing shareholder value.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's strong history of beating EPS estimates. However, concerns about revenue growth and pipeline developments linger.

Bull Case

If Bristol-Myers Squibb can deliver strong EPS and positive updates on its drug pipeline, it could lead to significant stock appreciation.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides disappointing updates on its pipeline, it could result in a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's strong history of EPS surprises, this number will be critical in determining market sentiment.

What updates will be provided on the drug pipeline?

Investors will closely watch for any advancements or setbacks in the pipeline, as these can significantly affect future revenue.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Bristol-Myers Squibb's pipeline to deliver unexpected results, particularly in oncology.

Supporting Evidence

The company has a strong track record of exceeding EPS estimates, with an 88% beat rate over the last eight quarters.

Options pricing suggests a relatively low expected move compared to historical averages, indicating potential for a larger surprise.

Key Risk

If pipeline updates reveal significant advancements, it could shift investor sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bristol-Myers Squibb can maintain its strong earnings trajectory amidst competitive pressures and pipeline challenges.

Bull Confirmed If

An EPS of $1.70 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.40 would raise concerns about profitability and future growth.

Pre-Earnings Positioning

Options Market

Implied Move

±4.83%

Historical Avg

±5.4%

In line with history

The options market is pricing in a move of about 4.83%, indicating that traders expect some volatility around the earnings announcement.

Options are pricing ±4.8% while BMY has averaged ±5.4% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

0.3%

30d HV

25.7%

Calls (1.0M)P/C Ratio: 1.07Puts (2.8M)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bristol-Myers Squibb beats EPS expectations, history suggests a potential stock increase of around 4.21%, confirming the bullish outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss on EPS could lead to a decline of about 5.81%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on the performance of key drugs in the pipeline.
2Updates on regulatory approvals or clinical trial results.
3Management's outlook on revenue growth for the upcoming quarters.
4Insights into cost management strategies and operational efficiency.
5Any changes in guidance or strategic priorities.